Recently, Hangzhou RoboCT Technology Development Co., Ltd. (hereinafter referred to as "RoboCT") announced the completion of a RMB 100 million Series B+ financing, marking the company's second round of financing within a year. This round was led by ABC Capital, with participation from Huichuan Capital and Hangzhou Capital. The funds raised will primarily be used for domestic and international market expansion of consumer-grade exoskeletons, R&D of embodied intelligent exoskeleton technology, registration of new brain-computer interface products, and channel marketing, further promoting the large-scale application of exoskeleton robotics in the consumer and elderly-care sectors.

From Rehabilitation to Widespread Consumer, Exoskeletons are Entering a New Era of "Human Enhancement"

Exoskeleton robotics are gradually breaking through the traditional scope of medical rehabilitation and rapidly penetrating into mass consumer scenarios. Industry data shows that the global wearable exoskeleton market reached $1.76 billion in 2024 and is projected to grow to $30.56 billion by 2032, with a compound annual growth rate exceeding 43%. In the Chinese market, the exoskeleton market is expected to reach 4.2 billion RMB in 2025, leading the world in growth rate. From scenic area mobility aids to home health assistance, consumer-grade exoskeletons are integrating into daily life in diverse forms, ushering in a new stage of human body enhancement.

WANG Tian, founder of RoboCT Technology, pointed out: "The essence of exoskeletons is the extension of human function. Just as drones have moved from professional use to mass consumption, exoskeletons will gradually cover various human activity scenarios, realizing the transformation from 'rehabilitation tools' to 'mobility partners.'"

AI Integration + Open Source, Aiming the New Consumer Exoskeleton Market

In the increasingly competitive consumer market, RoboCT leverages its full-stack self-developed capabilities to build a flexible and scalable product platform. The company has accumulated over 500 intellectual property rights and achieved complete independent control over core components and algorithms. Based on its outstanding technological innovation and industry leadership, RoboCT was successfully selected as a National-level Specialized, Refined, and Innovative Small Giant Enterprise in 2025.

Targeting the emerging domestic elderly care market, RoboCT launched the GoGo-H Exoskeleton, specifically designed for scenarios such as mobility assistance, community-based elderly care, and daily light assistance, truly making wearable exoskeletons a daily support partner for the elderly.

Meanwhile, Ascentiz, a new overseas brand of assistive exoskeletons under the company's ecosystem, garnered over 3,000 backers and raised over $2.5 million in just 45 days on the overseas crowdfunding platform Kickstarter, demonstrating strong product appeal and market recognition. Ascentiz is the world's first modularly designed wearable exoskeleton, supporting developer mode, full-dimensional customization settings, and reserving expansion interfaces, continuously upgrading its "hardware + service" capabilities.

Medical Accumulation Empowers Consumer Products, Independent R&D Builds Innovative Advantages

RoboCT has established a complete product matrix in the field of medical rehabilitation, serving over 920,000 patients. It has also collaborated with top institutions such as Xuanwu Hospital and Huashan Hospital to conduct clinical research on synergistic treatment using "neural interface + exoskeleton," successfully helping many patients regain their ability to walk. The accumulation of medical-grade technology and data provides a solid foundation for the human-machine collaboration accuracy and scenario adaptability of its consumer-grade products, enabling the company to successfully complete its strategic transformation from medical and healthcare to consumer applications. Being selected as a national-level specialized and innovative enterprise is an authoritative affirmation of RoboCT's achievements in core technology self-control and addressing shortcomings in key links of the industrial chain.

AI Integration + Scenario Expansion, Creating an Exoskeleton Platforms

RoboCT integrates AI large-scale models with high-precision sensing technology, achieving 100 human signal captures per second with a response time of less than 0.05 seconds and a recognition accuracy rate of 98.7%. The AI system can learn user habits and dynamically adjust assistance strategies, providing intelligent and personalized experiences in both medical and consumer scenarios.

Adhering to the development philosophy of its exoskeleton robotics platform, RoboCT continues to deepen its layout around five core scenarios: health, entertainment, transportation, logistics, and safety. Currently, the company's products have been successfully implemented in ground handling systems at multiple international airports, significantly improving operational efficiency and human-machine collaboration.

Looking to the future, RoboCT will continue to cultivate both professional and civilian markets, driving the evolution of exoskeletons from functional devices to intelligent and universally applicable human-machine integration carriers, striving to make them "human enhancement" that widely cover daily activities and professional scenarios. Through continuous expansion of technological boundaries and ecosystem cooperation, RoboCT hopes to make exoskeletons an important component empowering everyone, expanding physical potential and life possibilities, truly achieving a harmonious coexistence between technology and humanity!